TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better

Abstract

IL15 and TIGIT blockade enhances the natural killer (NK) cell–mediated activity against MHC-I–deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8þ T cell–mediated control.